Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–77. https://doi.org/10.1200/jco.21.01392.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023;129(7):1051–63. https://doi.org/10.1002/cncr.34675.

Article  CAS  PubMed  Google Scholar 

Li J, Huo X, Zhao F, et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(10):e2020312. https://doi.org/10.1001/jamanetworkopen.2020.20312.

Article  PubMed  PubMed Central  Google Scholar 

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–27. https://doi.org/10.1016/s0140-6736(20)30165-3.

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Harbeck N, Hegg R, et al. abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98. https://doi.org/10.1200/jco.20.02514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080–91. https://doi.org/10.1056/NEJMoa2305488.

Article  CAS  PubMed  Google Scholar 

Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH; Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J Clin Oncol. 2024;42(18):2233–2235. https://doi.org/10.1200/JCO.24.00886.

Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer. 2011;18(4):C19-24. https://doi.org/10.1530/erc-11-0112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–31. https://doi.org/10.1007/s40265-020-01461-2.

Article  CAS  PubMed  Google Scholar 

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30. https://doi.org/10.1038/nrclinonc.2016.26.

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35. https://doi.org/10.1016/s1470-2045(14)71159-3.

Article  CAS  PubMed  Google Scholar 

Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36. https://doi.org/10.1056/NEJMoa1607303.

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39. https://doi.org/10.1016/s1470-2045(15)00613-0.

Article  CAS  PubMed  Google Scholar 

Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19. https://doi.org/10.1056/NEJMoa1505270.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoa1609709.

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46. https://doi.org/10.1200/jco.2017.75.6155.

Article  CAS  PubMed  Google Scholar 

Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84. https://doi.org/10.1200/jco.2017.73.7585.

Article  CAS  PubMed  Google Scholar 

Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(-) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24. https://doi.org/10.1158/1078-0432.Ccr-17-0754.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224. https://doi.org/10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5485. https://doi.org/10.1158/1078-0432.CCR-18-3193.

Deng Y, Ma G, Li W, Wang T, Zhao Y, Wu Q. CDK4/6 inhibitors in combination with hormone therapy for HR(+)/HER2(-) advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Clin Breast Cancer. 2018;18(5):e943–53. https://doi.org/10.1016/j.clbc.2018.04.017.

Article  CAS  PubMed  Google Scholar 

Gao HF, Lin YY, Zhu T, et al. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. Breast. 2021;59:165–75. https://doi.org/10.1016/j.breast.2021.07.002.

Article  PubMed  PubMed Central  Google Scholar 

Xie N, Qin T, Ren W, Yao H, Yu Y, Hong H. Efficacy and safety of cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2- advanced breast cancer. Cancer Manag Res. 2020;12:4241–50. https://doi.org/10.2147/cmar.S254365.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Messina C, Cattrini C, Buzzatti G, et al. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172(1):9–21. https://doi.org/10.1007/s10549-018-4901-0.

Article  CAS  PubMed  Google Scholar 

Kappel C, Elliott MJ, Kumar V, Nadler MB, Desnoyers A, Amir E. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Sci Rep. 2024;14(1):3129. https://doi.org/10.1038/s41598-024-53151-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616–27. https://doi.org/10.1016/j.annonc.2022.03.006.

Article  CAS  PubMed  Google Scholar 

Diéras V, Harbeck N, Joy AA, et al. Palbociclib with letrozole in postmenopausal women with ER+/HER2- advanced breast cancer: hematologic safety analysis of the randomized PALOMA-2 trial. Oncologist. 2019;24(12):1514–25. https://doi.org/10.1634/theoncologist.2019-0019.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding L, Cao J, Lin W, et al. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int J Mol Sci. 2020;21(6). https://doi.org/10.3390/ijms21061960.

Zhang M, Song J, Guo S, Jin F, Zheng A. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis. Endocr Relat Cancer. 2023;30(8). https://doi.org/10.1530/erc-22-0365.

Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Bachelot T. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer. 2018;25(1):17–27. https://doi.org/10.1007/s12282-017-0818-4.